Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
- Submitting institution
-
Queen Mary University of London
- Unit of assessment
- 1 - Clinical Medicine
- Output identifier
- 2010
- Type
- D - Journal article
- DOI
-
10.1016/S0140-6736(17)32299-7
- Title of journal
- The Lancet
- Article number
- -
- First page
- 2063
- Volume
- 390
- Issue
- 10107
- ISSN
- 0140-6736
- Open access status
- Deposit exception
- Month of publication
- November
- Year of publication
- 2017
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
16
- Research group(s)
-
A - Blizard
- Citation count
- 110
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- I recruited the largest number of patients in the UK, was the only UK author in this multinational study leading to the registration and license of this drug for first line treatment. I contributed to data collection and to the review of all manuscript drafts, particularly interpretation of results and the discussion.
- Non-English
- No
- English abstract
- -
